Transpl Int
Transplant International
Transpl Int
1432-2277
Frontiers Media S.A.
11313
10.3389/ti.2023.11313
Health Archive
Correction
Corrigendum: Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient
Ueberdiek et al.
Corrigendum: Inclisiran After Kidney Transplantation
Ueberdiek
Lars
1
Jehn
Ulrich
1
Pavenstädt
Hermann
1
Gebauer
Katrin
2
Reuter
Stefan
1
*
1
Department of Medicine D, Transplant Nephrology, University Clinics Muenster, Muenster, Germany
2
Department of Cardiology I—Coronary and Peripheral Vascular Disease, Heart Failure, University Clinics Muenster, Muenster, Germany
*Correspondence: Stefan Reuter, stefan.reuter@ukmuenster.de
23
03
2023
2023
36
11313
27
02
2023
14
03
2023
Copyright © 2023 Ueberdiek, Jehn, Pavenstädt, Gebauer and Reuter.
2023
Ueberdiek, Jehn, Pavenstädt, Gebauer and Reuter
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient by Ueberdiek L, Jehn U, Pavenstädt H, Gebauer K and Reuter S (2023). Transpl. Int. 36:11104. doi: 10.3389/ti.2023.11104
kidney transplantation
renal transplantation
dyslipidemia
inclisiran
LDL
In the original article, there was an error. The injection type listed for the administration of Inclisiran was incorrect.
A correction has been made to paragraph 6:
“Inclisiran (284 mg i.m.) was administered at 0 and 3 months and then every 6 months while continuing atorvastatin and ezetimib.”
Has been updated to:
“Inclisiran (284 mg s.c.) was administered at 0 and 3 months and then every 6 months while continuing atorvastatin and ezetimibe.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.